Corona Remedies discloses sale of 4.58 million shares by three investors

What Corona Remedies announced

On 19 June 2026, Corona Remedies Ltd (BSE: 544644, NSE: CORONA) filed a disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 (SAST). The filing records the sale of equity shares by three separate investors – Sepia Investments Limited, Anchor Partners and Sage Investment Trust – that took place on 18 June 2026. The company’s secretary, Chetna Dharajiya, submitted the notice to both the Bombay Stock Exchange and the National Stock Exchange, as required by the regulations.

"We wish to inform you that Sepia Investments Limited, Anchor Partners and Sage Investment Trust have sold 4,328,943, 161,861 and 90,087 equity shares respectively of Corona Remedies Limited."

The filing does not disclose the price at which the shares were transferred, nor does it provide any commentary on the rationale behind the sales.

Details of the share sales

The combined volume of shares sold totals 4,580,891. All three investors are identified as separate parties in the disclosure, each having signed a separate cover letter dated 18 June 2026. Sepia Investments Limited is based in Mauritius, while Anchor Partners and Sage Investment Trust are indicated to have signed from Delhi, India.

Regulatory background

Regulation 29(2) of the SEBI SAST framework obliges any person who acquires or disposes of shares that cross the prescribed threshold (generally 1 % of the paid‑up capital) to inform the stock exchanges within two trading days of the transaction. The purpose is to ensure transparency in shareholding patterns and to alert the market to any substantial changes in control or influence over a listed entity.

In this case, the three investors have complied by filing the required notice, thereby allowing the exchanges to update Corona Remedies’ shareholding pattern. The filing does not indicate whether the transactions triggered any change in the control of the company; it merely records the share transfer.

Key facts at a glance

Why this matters for investors

The disclosure serves a purely compliance function: it records a material movement of shares that must be reflected in the company’s shareholding pattern. For existing shareholders, the key implications are:

• Potential dilution or concentration: While the filing does not state who bought the shares, the transfer could either dilute existing shareholders if the buyer is a new entrant, or consolidate holdings if the buyer is an existing large shareholder.
• Transparency: The filing ensures that the market is aware of the change, maintaining the integrity of the public record.
• No immediate financial impact disclosed: Because the price and consideration are not mentioned, investors cannot assess any direct financial effect on the company’s balance sheet or cash flows.
• Regulatory compliance: By filing within the stipulated timeline, Corona Remedies avoids penalties and demonstrates adherence to SEBI’s takeover code.

Conclusion

Corona Remedies Ltd has formally recorded the sale of 4,580,891 equity shares by Sepia Investments Ltd, Anchor Partners and Sage Investment Trust, as required under SEBI’s Regulation 29(2). The filing, submitted on 19 June 2026, provides the necessary transparency but does not reveal the transaction price or the identity of the purchasers. The shareholding pattern will be updated accordingly, and no further action is indicated in the disclosure.